Intraocular pressure and diurnal fluctuation of open-angle glaucoma and ocular hypertension: a baseline report from the LiGHT China trial cohort

Yangfan Yang,1 Xinyi Zhang,1 Zidong Chen,1 Yifan Wei,1 Qiaona Ye,1 Yanmei Fan,1 Neil Nathwani,2 Gus Gazzard,3,4 Minbin Yu,1 LiGHT China Trial Study Group

ABSTRACT

Aims To report the baseline intraocular pressure (IOP) characteristics and its diurnal fluctuation in the Laser in Glaucoma and Ocular Hypertension China cohort.

Methods 622 primary open-angle glaucoma (POAG) patients and 149 ocular hypertension (OHT) patients were recruited at Zhongshan Ophthalmic Center from 2015 to 2019. Standardised ocular examinations were performed including IOP measurement using the Goldmann application tonometer. Daytime phasing IOP was recorded at 8:00, 10:00, 11:30, 14:30, 17:00 hour.

Results The mean baseline IOP was 20.2 mm Hg for POAG patients and 24.4 mm Hg for OHT. Multiple regression analysis revealed that thicker central corneal thickness (CCT) was correlated with higher IOP in both POAG and OHT. Male gender and younger age were correlated with higher IOP only for POAG. As for diurnal IOP fluctuation, mean IOP fluctuation was 3.4 mm Hg in POAG eyes and 4.4 mm Hg in OHT. The peak and trough IOP occurred at 8:00 and 14:30 hour in both POAG and OHT eyes.

Conclusions Younger age, male gender and thicker CCT are correlated to higher IOP in POAG patients while only thicker CCT is related to higher IOP in OHT patients. Peak IOP appears mostly at early morning or late afternoon and trough value occurs mostly at early afternoon.

INTRODUCTION

Glaucoma, a group of disease characterised by optic nerve injury and progressive visual impairment, is regarded as one of the world’s leading causes of irreversible blindness. Although it is a multifactorial disease, intraocular pressure (IOP) remains the only modifiable risk factor for the condition. Evidence suggests that high IOP1–3 and IOP fluctuation4 are both potential risk factors for the onset and progression of glaucomatous optic neuropathy. Thus, it is of great clinical interest to fully understand characteristics of IOP in ocular hypertension (OHT) and primary open angle glaucoma (POAG) patients for glaucoma prevention and prognosis.

Many factors, including age,5,6 central cornea thickness (CCT)7–10 and spherical equivalent11,12 have been reported to be associated with IOP. However, all these results are inconsistent even in similar ethnicity and most of the studies are normal population based. Relatively little information on IOP and its related factors have been available in OHT or POAG patients.13,14 Since the ocular biometry can be different between normal and glaucoma eyes,15 the risk factors for normal subjects may or may not influence the IOP of POAG or OHT patients.14 On the other hand, it is acknowledged that IOP is not fixed, but varies during the 24-hour cycle.16 Therefore, monitoring a patient’s IOP during the daytime or over a 24-hour period known as phasing has obvious pragmatic benefits in the management of glaucoma.

The Laser in Glaucoma and Ocular Hypertension (LiGHT) China Trial is a single centre, prospective, randomised controlled trial, aiming to compare eye drops vs selective laser trabeculoplasty (SLT) as the first-line treatment for newly diagnosed patients with POAG or OHT. The purpose of this paper is to report the baseline IOP characteristics and its diurnal fluctuation in the LiGHT China cohort.

METHODS

Subjects

Eligible patients were recruited at the Zhongshan Ophthalmic Centre from March 2015 to January 2019. A total of 771 patients aged 18 years and above who met the eligibility criteria were enrolled in the LiGHT China. The details about the LiGHT China design have been published previously.17,18 Briefly, patients with newly diagnosed, untreated POAG in one or both eyes (including normal tension glaucoma (NTG)) or OHT qualifying for treatment, according to National Institute for Health and Care Excellence guidelines19 were enrolled. Exclusion criteria included contraindications to SLT, unable to accept randomisation, having visually significant cataract or were having treatment for another ophthalmic condition, having any history of treatment for POAG or OHT or previous intraocular surgery. Written informed consent was also obtained from all study participants.

Baseline IOP measurement

The key points of the protocol have been attached as an online supplemental appendix.20 The series of examinations started with a standardised questionnaire that consisted of questions on the participants’ personal information, general health condition, past history, family history, lifestyle and so forth. Complete ophthalmological examinations including Goldmann application tonometry (GAT), Schiotz tonometer, slit-lamp examination, gonioscopy, automated visual field test and Heidelberg Retinal Tomograph disc imaging were performed.
The refractive error was calculated as the spherical equivalent measured with an autorefractor (SE=spherical +1/2 cylindrical power). The CCT was measured with type A ultrasound. GAT was performed by technicians who had been trained followed the protocol and passed the consistency assessment before recruitment. The average of two readings was recorded and more readings were required if the difference between the first two readings is > 1 mm Hg. Calibration of tonometry was checked on a weekly basis. IOP phasing was not included in the protocol of the Trial but was an alternative diagnostic item. Daytime phasing IOP was recorded using GAT at five time-intervals during the day (8:00, 10:00, 11:30, 14:30, 17:00 hour). All examinations were based on standard operating procedures and performed by examiners blinded to trial.

Statistical analysis
Definitions of the terms used to describe fluctuation are shown below: (1) Peak IOP: highest IOP recorded in the stated time period; (2) Trough IOP: lowest IOP recorded in the stated time period; (3) IOP fluctuation: Peak IOP minus trough measured in the stated time period and (4) Mean amplitude of IOP excursions (MAPE): MAPE was calculated as the arithmetic mean value of the relevant IOP fluctuations meeting this criterion.19 All categorical data were represented by frequency with percentage and it was analysed by chi squared. Fisher’s exact test. Continuous data were presented by mean with SD and tested by Student’s t-test. Pearson correlation analysis and multivariate regression analysis were used to analyse the association with IOP. All p values were two sided and were considered statistically significant when p<0.05. Statistical analysis was carried out using a commercially available statistical software package (SPSS for Windows, V.26.0).

RESULTS
A total of 1105 POAG eyes and 271 OHT eyes of 771 participants (both eyes were eligible in 605 subjects, only the right eye was eligible in 73 subjects, and only the left eye in 93 subjects) were enrolled in the LiGHT China. Of the 1376 eyes identified, 945 POAG eyes and 264 OHT eyes accepted daytime phasing IOP measurements.

The mean age of the POAG patients was 49.76±17.19 years, and 364 (58.5%) were male. For OHT patients, the mean age was 38.81±14.69 years, and 72 (48.3%) were male. Mean IOP was 20.4±5.4 mm Hg for eyes diagnosed with POAG and 24.4±3.2 mm Hg for OHT eyes. OHT eyes had higher IOP and thicker CCT than POAG eyes with a statistical significance (p<0.001) (table 1). Notably, in patients with both eyes eligible, right eyes were more myopic than left eyes in both diagnostic groups (both p<0.05). Also, in POAG group, IOP of left eyes was higher than that of right eyes with a statistical significance (p=0.003) (table 2).

Pearson correlation analysis demonstrated that higher IOP was significantly correlated to thicker CCT and younger age in OHT group (all p<0.05). For POAG patients, younger age, male gender, thicker CCT, lower SE were all correlated with increasing IOP with a statistical significance (all p<0.01) (table 3). With regard to the results of multiple regression analysis, in both groups, higher IOP was still significantly correlated to thicker CCT (all p<0.05), but not with spherical equivalence. Additionally, a statistic significant correlation was noted between increasing IOP and male gender, younger age in POAG group (all p<0.01) while this correlation was not significant in OHT group (table 3).

As for the diurnal variation in IOP, the highest IOP (POAG: 18.7±5.1 mm Hg, OHT: 23.3±3.3 mm Hg) occurred at 8:00
DISCUSSION

IOP is an important indicator in the development and progression of glaucoma, thus fully understanding risk factors of elevated IOP and IOP fluctuation is of great significance. To our knowledge, this study is the first to report the baseline IOP, its associated factors and diurnal fluctuation of the POAG and OHT patients from the LiGHT China Trial.

The mean baseline IOP in OHT patients was 24.4±3.2 mm Hg, similar to 24.9±2.7 mm Hg reported in the Ocular Hypertension Treatment Study and other studies that included OHT patients. Average baseline IOP of POAG patients was 20.2±5.4 mm Hg, which was also similar to 20.7±4.1 mm Hg in the Early Manifest Glaucoma Trial and other studies. OHT eyes had significant higher baseline IOP and thicker CCT than POAG eyes in our cohort. As evidence, the results in our study have confirmed a positive relationship between IOP and CCT, which has been documented consistently in the literature. Our data revealed that an increase of 10 µm in CCT was associated with an increase of 0.21 mm Hg in OHT and 0.25 mm Hg in POAG, which close to a 0.23 mm Hg elevation reported in the Liwan Eye Study in China.

The role of age and its relationship with IOP still remains controversial. Numerous studies have discovered a positive association between older age and higher IOP level. However, in our study, multivariate analysis showed a significant negative correlation between age and IOP in POAG patients, consistent with the results of studies conducted in Asia populations. Ageing is relevant to reduced production of aqueous humor, which may be the reason for the reduction of IOP. But conversely, age-related structural changes in the trabecular meshwork can also increase the resistance to aqueous humour outflow and lead to elevated IOP. Briefly, different changes in aqueous humour circulation may have caused those two opposite results. As for the observed gender difference in IOP of POAG patients, it was hard to explain, probably because of hormonal difference.

Refractive error is postulated to influence IOP by altering the shape of the eye (axial elongation and scleral thinning) and subjecting it to greater stress as the spherical equivalent increases. In our study, multivariate analysis showed a significant negative association between IOP and SE, however, this association was not significant after controlling for age.

As a physical phenomenon, IOP is known to be dynamic with short-term and long-term fluctuations. In our study, multiple IOP measurements during office time demonstrated that IOP reached a peak early in the morning and decreased steadily during the day, which was similar with other studies. An average of 3.4 mm Hg IOP fluctuation in POAG eyes and 4.4 mm Hg in OHT eyes were reported in daytime phasing, and IOP fluctuation in OHT eyes was larger than that in OHT.

### Table 4 Daytime phasing IOP measurements of included eyes

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Mean IOP, mm Hg (mean±SD)</th>
<th>Peak IOP, mm Hg (mean±SD)</th>
<th>Trough IOP, mm Hg (mean±SD)</th>
<th>IOP fluctuation, mm Hg (mean±SD)</th>
<th>MAPE, mm Hg (mean±SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>POAG (n=945 eyes)</td>
<td>18.0±4.7</td>
<td>19.8±5.3</td>
<td>16.4±4.2</td>
<td>3.4±2.2</td>
<td>2.4±1.7</td>
</tr>
<tr>
<td>Mild POAG (n=598 eyes)</td>
<td>18.1±4.6</td>
<td>20.0±6.5</td>
<td>16.4±4.1</td>
<td>3.6±4.5</td>
<td>2.4±1.7</td>
</tr>
<tr>
<td>Moderate POAG (n=251 eyes)</td>
<td>18.2±5.0</td>
<td>20.0±5.6</td>
<td>16.5±4.5</td>
<td>3.5±2.3</td>
<td>2.4±1.7</td>
</tr>
<tr>
<td>Severe POAG (n=96 eyes)</td>
<td>17.7±4.6</td>
<td>19.2±5.0</td>
<td>16.1±4.2</td>
<td>3.1±1.9</td>
<td>2.1±1.3</td>
</tr>
<tr>
<td>NTG (n=540 eyes)</td>
<td>15.1±2.5</td>
<td>16.7±4.9</td>
<td>13.8±2.3</td>
<td>2.9±4.4</td>
<td>1.9±1.2</td>
</tr>
<tr>
<td>OHT (n=264 eyes)</td>
<td>22.1±2.7</td>
<td>24.4±3.2</td>
<td>20.2±4.2</td>
<td>4.2±4.4</td>
<td>2.8±1.6</td>
</tr>
</tbody>
</table>

The severity of POAG is classified according to MD value of baseline visual field (mild POAG: MD value ≥6; moderate POAG: −6>MD value ≥12; severe POAG: MD values<12). IOP, intraocular pressure; MAPE, mean amplitude of IOP excursion; NTG, normal tension glaucoma; OHT, ocular hypertension; POAG, primary open-angle glaucoma.
eyes, which were both within ‘normal’ range.16 The MAPE of OHT eyes was also higher than that of POAG eyes. Besides, the mean MAPE of POAG eyes in our study was 4.18 mm Hg and similar to the mean MAPE reported in another study (4.16 mm Hg).18 The daytime phasing demonstrated significant larger variation in IOP of OHT eyes than POAG eyes, possibly supporting the findings that IOP fluctuation might not be an independent risk factor for conversion from OHT to glaucoma. 29, 30 It is also interesting to mention that in both POAG and OHT patients the right eyes were more myopic than left eyes, which confirmed the findings that right eyes have longer axial length than left eyes.14 However, the interocular IOP difference noted only in POAG patients was difficult for us to explain.

Potential limitations of our study should also be discussed. First, 24 hours IOP phasing with large sample size should be needed to get more accurate results, which will be shown in our other studies. Besides, risk factors in our study are still limited. Some parameters, such as ambulatory blood pressure9 11 and axial length,12 proved to be potential predictors of IOP were not included in our study.

In conclusion, for POAG patients, higher IOP is correlated to younger age, male gender, thicker CCT, whereas in patients with OHT, only thicker CCT seems to be risk factors of higher IOP. IOP of POAG or OHT eyes varies and reaches the peak value mostly at early morning or late afternoon and the trough value mostly at early afternoon.

Twitter Gus Gazzard @gusgazzard

Acknowledgements We are grateful to Xucui Cai, Liming Chen, Xin Yi, Yuning Zhang, Mingjie Deng, Zhikun Ouyang, Xiaoxiao Cai, Zongyi Zhan, Shitong Huang, Yunzhi Xu for their contribution to the collection of baseline data. Thanks to Amanda Davis for her valuable help during preparation and recruitment, and Emily Dowse for her efforts on data quality.

Contributors YF and XZ performed the analysis of the data, and contributed equally in writing the manuscript. ZC and YW were contributors in data collection and quality control. QY and YF contributed to the revision. YF and NN contributed to data quality control. GG and MY were the leader of the study group, designed and in charge of the study, and were also responsible for quality control of the trial. MY was responsible for the overall content as guarantor. All authors read and approved the final manuscript.

Funding This work was supported by the Moorfields Eye Charity (grant number 166186); the British Council for Prevention Of Blindness (grant number 165223) and the Natural Science Foundation of Guangdong Province (grant number 2021A1515010604).

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval The study design followed the tenets of the Declaration of Helsinki and had been approved by ethical committee of Zhongshan Ophthalmic Center, Sun yat-sen University (reference number 2014MEK0154).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Gus Gazzard http://orcid.org/0000-0002-1982-5005
Mintin Yu http://orcid.org/0000-0002-3938-7164

REFERENCES


Clinical science

Appendix

Key protocol of LiGHT China Trial

a. Eligibility criteria, operational definition of OAG & OHT;

We have used the NICE recommended thresholds for initiating treatment\(^1\), with stringent diagnostic definitions of disease (OAG or OHT) for entry into the study. Unicocular patients are eligible.

1.1 Diagnosis of OAG

Open Angle Glaucoma is defined as an open drainage angle with no secondary causes (such as trauma):

1. and reproducible glaucomatous visual field (VF) defects as tested by the SITA Standard white-on-white 24-2 algorithm on the Humphrey Visual Field Analyser (HVF) (i.e. reproducible defect, in at least, of two or more contiguous points with \(P < 0.01\) loss or greater, or three or more contiguous points with \(P<0.05\) loss or greater, or abnormal Glaucoma Hemifield Test, GHT);

2. or GON with localised absence of the neuro-retinal rim or, cup disc ratio of 0.7 or more, or asymmetry of cup disc ratio of 0.2 or more in similar sized eyes / optic discs.

And deemed to require treatment in the opinion of glaucoma specialist.

Subjects with pseudo-exfoliation are eligible, subjects who have undergone less than 4 weeks of medical treatment from their primary care ophthalmologists as a temporising control measure (with medications other than prostaglandins) will be permitted to enter the study, but will be required to undergo a 4-week washout period to establish their baseline IOP. Subjects with GON and IOP in the normal range are eligible. ‘Phasing’ (diurnal IOP pressure measurements) will be performed at the discretion of the treating clinician and if performed the maximum IOP recorded will be used as that day’s measurement.

1.2 Diagnosis of OHT

OHT with IOP above 21mmHg and requiring treatment as per NICE Guidelines. NICE OHT guidelines treat 4 categories of OHT on the basis of central corneal...
thickness (CCT) and age (the rest are monitored for 3-5 years).

b. **Criteria for treatment escalation decisions**

   Treatment will be escalated under the following circumstances:
   
   1. “Strong Evidence” of progression (as defined below) irrespective of IOP.
   2. IOP above Target by more than a certain threshold at a single visit (irrespective of evidence for progression)
   3. IOP above Target by less than threshold plus “Less Strong Evidence” for progression. If the IOP is above Target by less than threshold with no evidence for progression, then the 'Treatment Target IOP' will be re-evaluated. More detail of the indications for treatment escalation and 'Treatment Target IOP' re-evaluation, to deal with specific clinical scenarios, is given in the full version protocol of the trial.

c. **Method and unit of randomization (eyes/patients)**

   Randomization will be carried out according to a trial specific SOP. Online randomization (with blocking with random block sizes) will be used to randomize at the level of the patient and be stratified by diagnosis (OHT/OAG). The primary analysis will adjust for the stratification factor used in randomization. Participants will be randomized to medication or SLT group in equal proportion using a web-based randomization service provided by a specialist company to achieve full allocation concealment ([www.sealedenvelope.co.uk](http://www.sealedenvelope.co.uk)). ‘Sealed Envelope’ will also hold the randomization list. A backup telephone service will be available. The incremental escalation of treatment flow-chat displays the procedure of the trial (**Figure A**).
Figure A. Incremental escalation of treatment flow-chart.

d. Outcome measures

1. The primary outcome measure is Health Related Quality of Life (HRQL).

2. The secondary outcome measures including:

2.1 Treatment Pathway Cost and Cost-Effectiveness
2.2 Glaucoma-specific treatment-related quality of life: Glaucoma Utility Index (GUI)

2.3 Patient Reported Visual Function: VF-14

2.4 Other secondary outcomes: Patient Reported Disease and Treatment Related Symptoms: Glaucoma Symptom Scale83 (GSS), Patient Reported Visual Function: Glaucoma Quality of Life - 1510 (GQL-15), Objective measures of pathway effectiveness and visual function, Objective measures of the safety profiles of each pathway.

e. Specific statement as to whether participants signed a consent document should be included.

Informed consent was obtained from all individual participants included in the study. And all patients will be given a Patient Information Leaflet (PIL) and a copy of the Informed Consent. The original signed form will be retained at the study site. Vulnerable groups who would have difficulty in giving informed consent will not form part of this study. Patients who are unable to read Chinese but are able to retain and understand oral information about the study will be permitted to enter the study with an independent witness to counter-sign the consent form.

f. Method for assessment of ocular and systemic conditions

The baseline assessments will be done once the patient has been entered into the trial and before their first treatment. These will be the same as the screening assessment (slit-lamp examination, automated visual field test, HRT disc imaging, and KOWA simultaneous stereo digital disc photography) with the addition of self-completed baseline questionnaires (EQ5-D Glaucoma Utility Index (GUI), Glaucoma Symptom Scale (GSS), Glaucoma Quality of Life - 15 (GQL-15; a visual function measure) and Visual Function 14 (VF-14; a Chinese-validated function measure).

All patients will undergo a comprehensive medical history inquiry to find out if they had any history of other systemic diseases. The subjects will be tested for blood pressure and blood sugar to determine whether they had hypertension, diabetes,
asthma, angina, cardiac arrhythmia, ischaemic heart disease, migraines, cerebrovascular accident/stroke, peripheral vasospastic symptoms or blood loss/transfusion.

**Full version of protocol is available via the link as following:**